Chronic Kidney Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033

About GlobalData

1 Chronic Kidney Disease: Executive Summary

1.1 The CKD market will exhibit strong growth between 2023 and

2033.

1.2 Label expansions of cardiovascular drugs will fuel market growth.

1.3 Unmet needs remain in the CKD market despite the availability of well-established therapies.

1.4 Oral agents will dominate the CKD market.

1.5 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or staging systems

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 7MM forecast methodology.

4.4.1 Sources

4.4.2 Forecast assumptions and methods.

4.4.3 Total prevalent cases of CKD

4.4.4 Total prevalent cases of CKD by stage

4.4.5 Diagnosed prevalent cases of CKD.

4.4.6 Diagnosed prevalent cases of CKD by stage.

4.4.7 Diagnosed prevalent cases of CKD based on dialysis dependence.

4.5 Epidemiological forecast for CKD (2023-33)

4.5.1 Total prevalent cases of CKD

4.5.2 Total prevalent cases of CKD by stage

4.5.3 Diagnosed prevalent cases of CKD.

4.5.4 Age-specific diagnosed prevalent cases of CKD

4.5.5 Sex-specific diagnosed prevalent cases of CKD

4.5.6 Diagnosed prevalent cases of CKD by stage.

4.5.7 Diagnosed prevalent cases of CKD by dialysis dependence.

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact.

4.6.3 Limitations of the analysis

4.6.4 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Lack of efficacious drugs

7.3 Drug cost and market access

7.4 Lack of education and awareness of new products

7.5 Compliance and optimal management of CKD treatments

8 R&D Strategies

8.1 Overview

8.1.1 Label expansion for therapies approved for other indications.

8.1.2 Mergers and acquisitions to expand the product pipeline.

8.2 Clinical trials design

8.2.1 Clinical endpoints for CKD

8.2.2 Inclusion and exclusion criteria

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Seven major markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global Issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – KOLs interviewed for this report.

13.4.1 KOLs

13.5 Primary research – prescriber survey

13.6 About the authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Vice President of Disease Intelligence and Epidemiology

13.6.5 Global Head of Pharma Research, Analysis, and Competitive Intelligence

Contact Us

Table 1: CKD: key metrics in the 7MM

Table 2: Stages of CKD

Table 3: KDIGO classification of CKD

Table 4: Risk factors and comorbid conditions associated with CKD

Table 5: Common diagnostic tests for CKD

Table 6: Treatment guidelines for CKD

Table 7: Top 10 deals by value, 2022–24

Table 8: CKD market – global drivers and barriers, 2023–33

Table 9: Key events impacting sales for CKD in the US, 2023–33

Table 10: CKD Market – Drivers and Barriers in the US, 2023–33

Table 11: Key events impacting sales for CKD in the 5EU, 2023–33

Table 12: CKD Market – Drivers and Barriers in the 5EU, 2023–33

Table 13: Key events impacting sales for CKD in Japan, 2023–33

Table 14: CKD Market – Drivers and Barriers in Japan, 2023–33

Table 15: High-prescribing physicians (non-KOLs) surveyed, by country

Figure 1: Global sales forecast by country for CKD in 2023 and 2033

Figure 2: Analysis of the company portfolio gap in CKD during the forecast period

Figure 3: Competitive assessment of the oral late-stage pipeline agents that GlobalData expects to be licensed for the treatment of CKD during the forecast period

Figure 4: Competitive assessment of the injectable late-stage pipeline agents that GlobalData expects to be licensed for the treatment of CKD during the forecast period

Figure 5: The etiology of CKD

Figure 6: The pathophysiology of CKD

Figure 7: 7MM, diagnosed prevalence of CKD (%), men, ages ≥18 years, 2023

Figure 8: 7MM, total prevalence of CKD (%), women, ages ≥18 years, 2023

Figure 9: 7MM, sources used and not used to forecast the total prevalent cases of CKD

Figure 10: 7MM, sources used to forecast the total prevalent cases of CKD by stage

Figure 11: 7MM, sources used to forecast the diagnosed prevalent cases of CKD

Figure 12: 7MM, sources used to forecast the diagnosed prevalent cases of CKD by stage

Figure 13: 7MM, sources used to forecast the diagnosed prevalent cases of CKD by dialysis dependence

Figure 14: 7MM, total prevalent cases of CKD, N, both sexes, ages ≥18 years, 2023

Figure 15: 7MM, total prevalent cases of CKD by stage, N, both sexes, ages ≥18 years, 2023

Figure 16: 7MM, diagnosed prevalent cases of CKD, N, both sexes, ages ≥18 years, 2023

Figure 17: 7MM, diagnosed prevalent cases of CKD by age group, N, both sexes, 2023

Figure 18: 7MM, diagnosed prevalent cases of CKD by sex, N, ages ≥18 years, 2023

Figure 19: 7MM, diagnosed prevalent cases of CKD by stage, N, both sexes, ages ≥18 years, 2023

Figure 20: 7MM, diagnosed prevalent cases of CKD by dialysis dependence, N, both sexes, ages ≥18 years, 2023

Figure 21: 7MM, diagnosed prevalent cases of CKD based on dialysis-dependence subtype, N, both sexes, ages ≥18 years, 2023

Figure 22: Unmet needs and opportunities in CKD

Figure 23: Overview of the development pipeline in CKD

Figure 24: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for the treatment of CKD in the 7MM during the forecast period

Figure 25: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of CKD during the forecast period

Figure 26: Competitive assessment of the oral pipeline drugs benchmarked against the standard of care

Figure 27: Competitive assessment of the injectable pipeline drugs benchmarked against the standard of care

Figure 28: Analysis of the company portfolio gap in CKD during the forecast period

Figure 29: 7MM sales forecast by country for CKD in 2023 and 2033

Figure 30: Sales forecast by class for CKD in the US in 2023 and 2033

Figure 31: Sales forecast by class for CKD in the 5EU in 2023 and 2033

Figure 32: Sales forecast by class for CKD in Japan in 2023 and 2033